Intrexon Corp. (XON) Shares Down 2.7%
Shares of Intrexon Corp. (NYSE:XON) were down 2.7% during trading on Wednesday . The stock traded as low as $26.77 and last traded at $27.13, with a volume of 632,455 shares traded. The stock had previously closed at $27.88.
Several analysts have commented on XON shares. Vetr raised shares of Intrexon Corp. from a “strong sell” rating to a “buy” rating and set a $27.01 price objective on the stock in a research report on Thursday, July 28th. Griffin Securities reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Intrexon Corp. in a research report on Tuesday, August 16th. JMP Securities reaffirmed a “buy” rating on shares of Intrexon Corp. in a research report on Sunday, July 17th. Zacks Investment Research lowered shares of Intrexon Corp. from a “buy” rating to a “hold” rating in a research report on Friday, August 12th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $57.00 price objective on shares of Intrexon Corp. in a research report on Wednesday, June 29th. Three analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $41.71.
The firm’s market cap is $3.33 billion. The stock’s 50 day moving average is $27.32 and its 200-day moving average is $28.75.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/intrexon-corp-xon-shares-down-2-7.html
Intrexon Corp. (NYSE:XON) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.16. Intrexon Corp. had a negative return on equity of 19.00% and a negative net margin of 96.65%. The business earned $52.50 million during the quarter, compared to the consensus estimate of $53.78 million. During the same quarter last year, the company earned ($0.37) EPS. Intrexon Corp.’s revenue for the quarter was up 17.0% on a year-over-year basis. On average, equities research analysts expect that Intrexon Corp. will post ($1.36) EPS for the current year.
In other Intrexon Corp. news, SVP Nir Nimrodi acquired 4,000 shares of the stock in a transaction dated Monday, August 29th. The shares were purchased at an average price of $26.12 per share, for a total transaction of $104,480.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 55.10% of the stock is currently owned by insiders.
A number of large investors have recently added to or reduced their stakes in XON. Macquarie Group Ltd. purchased a new stake in Intrexon Corp. during the second quarter worth approximately $679,000. Stifel Financial Corp boosted its stake in Intrexon Corp. by 15.4% in the second quarter. Stifel Financial Corp now owns 40,483 shares of the company’s stock worth $997,000 after buying an additional 5,413 shares during the last quarter. Amalgamated Bank purchased a new stake in Intrexon Corp. during the second quarter worth approximately $253,000. Legal & General Group Plc boosted its stake in Intrexon Corp. by 53.6% in the second quarter. Legal & General Group Plc now owns 5,819 shares of the company’s stock worth $144,000 after buying an additional 2,031 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its stake in Intrexon Corp. by 13.7% in the second quarter. Metropolitan Life Insurance Co. NY now owns 4,161 shares of the company’s stock worth $102,000 after buying an additional 501 shares during the last quarter. Institutional investors own 84.05% of the company’s stock.
Intrexon Corp. Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.
Receive News & Ratings for Intrexon Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corp. and related companies with MarketBeat.com's FREE daily email newsletter.